Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Increases By 9.2%

Candel Therapeutics, Inc. (NASDAQ:CADL) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 160,900 shares, an increase of 9.2% from the March 15th total of 147,300 shares. Based on an average trading volume of 3,880,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 1.0% of the shares of the company are short sold.

Institutional Trading of Candel Therapeutics

A number of large investors have recently modified their holdings of the business. Point72 Asset Management L.P. bought a new stake in Candel Therapeutics in the 2nd quarter worth approximately $2,408,000. Citigroup Inc. bought a new stake in Candel Therapeutics in the 2nd quarter worth approximately $149,000. Vanguard Group Inc. lifted its position in Candel Therapeutics by 5.4% in the 4th quarter. Vanguard Group Inc. now owns 425,749 shares of the company’s stock worth $626,000 after buying an additional 21,680 shares during the last quarter. Renaissance Technologies LLC bought a new stake in Candel Therapeutics in the 1st quarter worth approximately $28,000. Finally, BlackRock Inc. lifted its position in Candel Therapeutics by 15.5% in the 1st quarter. BlackRock Inc. now owns 132,322 shares of the company’s stock worth $674,000 after buying an additional 17,708 shares during the last quarter. Institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Stock Performance

CADL traded up $0.07 during trading hours on Tuesday, hitting $5.89. The stock had a trading volume of 1,072,389 shares, compared to its average volume of 4,517,694. The company’s fifty day simple moving average is $2.33 and its 200 day simple moving average is $1.52. Candel Therapeutics has a 1 year low of $0.66 and a 1 year high of $11.40. The stock has a market cap of $172.87 million, a PE ratio of -4.76 and a beta of 0.92. The company has a quick ratio of 2.59, a current ratio of 2.59 and a debt-to-equity ratio of 0.97.

Candel Therapeutics (NASDAQ:CADL) last posted its earnings results on Thursday, March 28th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.22). Equities analysts anticipate that Candel Therapeutics will post -0.91 earnings per share for the current year.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.